ES2084995T3 - Composicion farmaceutica para el tratamiento de enfermedades malignas de los linfocitos b. - Google Patents

Composicion farmaceutica para el tratamiento de enfermedades malignas de los linfocitos b.

Info

Publication number
ES2084995T3
ES2084995T3 ES92901009T ES92901009T ES2084995T3 ES 2084995 T3 ES2084995 T3 ES 2084995T3 ES 92901009 T ES92901009 T ES 92901009T ES 92901009 T ES92901009 T ES 92901009T ES 2084995 T3 ES2084995 T3 ES 2084995T3
Authority
ES
Spain
Prior art keywords
treatment
lymphocytes
pharmaceutical composition
malignant diseases
cell malignances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92901009T
Other languages
English (en)
Inventor
Jacques Banchereau
France Thierry De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schering Plough Corp
Original Assignee
Schering Plough Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Corp filed Critical Schering Plough Corp
Application granted granted Critical
Publication of ES2084995T3 publication Critical patent/ES2084995T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE MALIGNIDADES DE CELULAS B EN UNA MAMA AFECTADA CON ESTAS MALIGNIDADES DE CELULAS B. DE FORMA MAS PRECISA, DE ACUERDO CON LA INVENCION, ESTAS COMPOSICIONES FARMACEUTICAS COMPRENDEN IL-4 COMO UN INGREDIENTE ACTIVO. LA PRESENTE INVENCION SE REFIERE TAMBIEN A UN METODO DE TRATAMIENTO DE MALIGNIDADES DE CELULAS B, O A LA INHIBICION DE LA PROLIFERACION O CRECIMIENTO DE CELULAS B MALIGNAS MEDIANTE LA ADMINISTRACION DE IL-4 A MAMAS QUE ESTAN AFECTADAS CON MALIGNIDADES DE CELULAS B.
ES92901009T 1990-12-13 1991-12-10 Composicion farmaceutica para el tratamiento de enfermedades malignas de los linfocitos b. Expired - Lifetime ES2084995T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90403585A EP0490006B1 (en) 1990-12-13 1990-12-13 Pharmaceutical compositions for the treatment of B-cell malignancies

Publications (1)

Publication Number Publication Date
ES2084995T3 true ES2084995T3 (es) 1996-05-16

Family

ID=8205785

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92901009T Expired - Lifetime ES2084995T3 (es) 1990-12-13 1991-12-10 Composicion farmaceutica para el tratamiento de enfermedades malignas de los linfocitos b.

Country Status (16)

Country Link
EP (2) EP0490006B1 (es)
JP (1) JPH06504767A (es)
AT (1) ATE135232T1 (es)
AU (1) AU9072191A (es)
CA (1) CA2098509A1 (es)
CZ (1) CZ113593A3 (es)
DE (1) DE69117974T2 (es)
DK (1) DK0561927T3 (es)
ES (1) ES2084995T3 (es)
FI (1) FI932650A7 (es)
GR (1) GR3019699T3 (es)
HU (1) HU210009B (es)
IE (1) IE64157B1 (es)
OA (1) OA09788A (es)
SK (1) SK59193A3 (es)
WO (1) WO1992010201A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004179A1 (en) * 1992-08-19 1994-03-03 Schering Corporation Method for inhibiting hiv replication using il-4
US5679338A (en) * 1994-05-12 1997-10-21 Osteoarthritis Science, Inc. Use of IL-4 for inhibition of the breakdown of articular cartilage and other tissues
US5716612A (en) * 1994-09-07 1998-02-10 Schering Corporation Use of IL-4 for potentiation of chemotherapeutic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0552243T3 (da) * 1990-09-06 1997-03-10 Schering Corp Anvendelse af interleukin-4 til behandling af faste tumorer

Also Published As

Publication number Publication date
DK0561927T3 (da) 1996-07-29
EP0561927B1 (en) 1996-03-13
FI932650L (fi) 1993-06-10
FI932650A0 (fi) 1993-06-10
EP0490006B1 (en) 1994-06-22
CZ113593A3 (en) 1994-01-19
JPH06504767A (ja) 1994-06-02
IE914328A1 (en) 1992-06-17
CA2098509A1 (en) 1992-06-14
HUT64478A (en) 1994-01-28
HU210009B (en) 1995-01-30
EP0561927A1 (en) 1993-09-29
OA09788A (en) 1994-04-15
HU9301719D0 (en) 1993-09-28
DE69117974T2 (de) 1996-07-25
AU9072191A (en) 1992-07-08
EP0490006A1 (en) 1992-06-17
FI932650A7 (fi) 1993-06-10
DE69117974D1 (de) 1996-04-18
WO1992010201A1 (en) 1992-06-25
GR3019699T3 (en) 1996-07-31
IE64157B1 (en) 1995-07-12
ATE135232T1 (de) 1996-03-15
SK59193A3 (en) 1994-01-12

Similar Documents

Publication Publication Date Title
ES2148838T3 (es) Oligonucleotidos antisentido contra la subunidad reguladora alfa de la proteina quinasa dependiente de camp para el tratamiento del cancer.
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
AR025444A1 (es) Derivados de sulfonil-carboxamida, procedimientos para su preparacion y su utilizacion como medicamentos
CO4290424A1 (es) Pirazolopiridinas, pirrolopiridinas, composiciones farmaceu- ticas que las contienen y procedimientos para su administra- cion como antagonista del factor de liberacion de cortico- tropina
AR023346A1 (es) Compuestos derivados biciclicos substituidos utiles como agentes contra el cancer, uso de los mismos para preparar un medicamento, composicionesfarmaceuticas y procedimiento de preparacion de los compuestos
ES2190674T3 (es) Uso de n-alquil derivados de cadena larga de desoxinojirimicina para la fabricacion de un medicamento para el tratamiento de enfermedades de acumulacion de glucolipidos.
AR020019A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de cancer de mama
AR023956A1 (es) Articulo interlabial absorbente
AR022860A1 (es) Derivados de camptotecina que poseen actividad antitumoral
EA200101046A1 (ru) Производные индигоидных бис-индолов
ES2182161T3 (es) Utilizacion de derivados de pirimidina para la preparacion de un medicamento para la prevencion del cancer.
ES2097341T3 (es) Indoles sustituidos como farmacos para el tratamiento del sida.
ES2172937T3 (es) 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
AR033957A1 (es) Nuevos compuestos
UY25356A1 (es) Polisacaridos de sintesis,procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
SE9900070D0 (sv) New use
ES2084995T3 (es) Composicion farmaceutica para el tratamiento de enfermedades malignas de los linfocitos b.
AR028947A1 (es) Compuestos novedosos
SV2002000179A (es) Proceso para la preparacion de un compuesto para reducir el riesgo del cancer ref.x-13527-el
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
ES2063574T3 (es) Metodo de tratamiento mejorado para el cancer.
ES2167721T3 (es) Utilizacion de 1-hidroxi-2-piridonas para el tratamiento de la dermatitis seborreica.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
MX9300406A (es) Derivados azabiciclicos procedimientos para su preparacion y composiciones que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 561927

Country of ref document: ES